DRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine
نویسندگان
چکیده
Background Identification of immune biomarkers indicating potential clinical benefit from immunotherapies may contribute to the selection of the right patient for the right therapy. We have recently reported that HLA-DRB1*11 and HLA-A*24 alleles might serve as predictive factors for immunological and clinical responses to vaccination with AE37, the Ii-Key hybrid peptide of HER2776-790 (AE36) in prostate cancer patients. The purpose of this study was to investigate the predictive significance of DRB1*11 allele expression in relation to immunological and clinical response in breast cancer patients vaccinated with AE37 in a randomized Phase II clinical trial.
منابع مشابه
Further insight into AE37 peptide vaccination in prostate cancer
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host [1]. Although the rationale of cancer vaccination studies s...
متن کاملCorrelation of HER2/neu antibody response to clinical response in a Phase II trial of the ae37+gm-csf her2 peptide vaccine
Background We are conducting a Phase II clinical trial of the HER2 peptide vaccine AE37+GM-CSF for prevention of breast cancer recurrence in disease-free, node-positive or highrisk node-negative patients, who have completed standard of care therapy. AE37, an Ii-Key hybrid of the HER2/neu derived peptide AE36 (aa:776-790), is an MHC Class II epitope capable of stimulating CD4 helper T cells. Her...
متن کاملThe impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
PURPOSE HER2/neu, a source of immunogenic peptides, is expressed in >75% of breast cancer patients. We have conducted clinical trials with the HER2/neu E75 peptide vaccine in breast cancer patients with varying levels of HER2/neu expression. Vaccine response based on HER2/neu expression level was analyzed. EXPERIMENTAL DESIGN Patients were stratified by HER2/neu expression. Low expressors (n ...
متن کاملImmunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice
Objective(s): Breast cancer is one of the most common cancers in the world and is on the increase. MUC1 and HER2 as tumor-associated antigens (TAAs) are abnormally expressed to some extent in 75–80% of breast cancers. In our present research, a novel chimeric MUC1-HER2 (HM) protein was designed and used to study whether an immune response can be generated against these TAAs. In vitro analysis ...
متن کاملConcurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
PURPOSE The primary objectives of this phase I/II study were to evaluate the safety and immunogenicity of combination therapy consisting of concurrent trastuzumab and human epidermal growth factor receptor 2 (HER2)/neu-specific vaccination in patients with HER2/neu-overexpressing metastatic breast cancer. PATIENTS AND METHODS Twenty-two patients with stage IV HER2/neu-positive breast cancer r...
متن کامل